Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. - Wikidata - awgldk - TriplyDB

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

http://www.wikidata.org/entity/Q35965389

about

Toxicity management of immunotherapy for patients with metastatic melanoma High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers Gaps in nutritional research among older adults with cancer Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports Immune Checkpoint in Glioblastoma: Promising and Challenging Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis.Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab.Fundamental effects of PD-1 antibody on the body: a brief report.Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.Fulminant Myocarditis with Combination Immune Checkpoint Blockade.Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy.Immune checkpoint inhibitors in lung cancer: past, present and future.Immune-Related Adverse Events From Immune Checkpoint Inhibitors.Immune checkpoint inhibitors side effects and management.Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.Case report of nivolumab-related pneumonitis.Pembrolizumab-induced pneumonitis.Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)

P2860

Q26738662-75D453E2-9E33-451A-8B09-549EFE837FE9 Q27300777-5A5EF4C1-AC69-474A-935C-1DEBBBAC0D7F Q28067552-76DDA740-5118-4E58-A54D-91FF91F1B2FA Q28553328-BA660F48-0A82-4484-98D2-2BC18C08B28F Q33650058-C20C59D8-E8D0-48EE-9263-18039F9AC30A Q33738859-5608D8E7-D776-4362-B425-C4E3E03FE533 Q33813378-FE374902-BB10-4764-BD51-3CC30D351B86 Q36494977-F9693BEE-BB63-4E55-A2FF-AFD2AB483112 Q36634979-D77E9F30-9D36-4020-A7B8-04478ABB25E4 Q36687229-E799E5A7-B70C-4225-8AB9-1E9E3D531B37 Q36759340-392C1B66-CCFE-4642-9E43-E6310D9656CE Q36927249-DAA1EA8E-92D9-4176-84F7-8A637506F315 Q37082763-FFD0C881-5AE8-4275-BA6C-46FD554407E6 Q37262696-1E535169-2D11-431E-B55A-539124407B80 Q37303319-E0B7300D-FBF8-485E-947F-DA69CA923DF6 Q37526782-303F5B91-55FD-46F5-A138-0EA443E445FB Q37589557-0D2314DA-5D0F-4F91-95F8-4AE8ED9E115C Q37595462-1574920A-1377-49D9-82DA-CD896791A739 Q37675967-F493A4FA-3C6F-41C0-AB18-804327C0759E Q37685959-93086301-9179-4D02-96BA-2F4DE34949E6 Q38586991-E1E01B86-CE8F-4F2B-A772-F0B244349138 Q38751328-756BA979-8A64-4D3C-9753-40C45558B561 Q38791209-14A00683-B47B-49D7-B42C-3F9FE6C66F64 Q38832640-318ECA67-591E-4F7F-A265-076D57E04E98 Q38878899-961BC5FE-8FAC-4DAB-8B36-0E058BE8FAA7 Q38884560-776725FE-055B-4CFE-B370-7DE07EE1F889 Q38915130-9A8147CB-90DB-4399-B257-8A5E923227BF Q38919707-AC17C65A-909F-437D-B038-369B48DFAB7A Q39227781-DDCF4040-C622-4376-9A94-CEF316F12C50 Q39270453-E034F5D2-804D-48B4-86A0-336924E5E885 Q39308337-4F44DE9A-644E-4A6A-9425-5996917876CB Q39430042-B592DE1E-B6B8-4863-8518-A58BC654F42B Q39947131-4D0EE13E-4A66-4E05-AA2A-CED55F9486A5 Q40064825-E17EFE1C-DD62-4676-B877-5305506F74C1 Q40222948-534EC4EA-CC42-48D9-8C6E-C8F2AD205C52 Q40534742-17D82736-E26F-4111-BBCA-7C2F8094F322 Q41356383-B3E06A0D-5D29-4EC2-9B9C-FFAC07E0C322 Q41728425-EB9C4102-9E20-4E21-8992-BE044F55F214 Q41896400-27221DF0-1E63-41F1-82FE-3577C3F2476D Q42264783-4AC90466-D50D-4BA1-9D19-68CEE52E6FB6

P2860

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

http://www.wikidata.org/entity/Q35965389

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

@ast

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

@en

type

label

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

@ast

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

@en

prefLabel

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

@ast

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

@en

P1433

Q35965389-B9B1B5C2-3E65-4F0E-BD4E-EFA36E713414

P1476

Q35965389-B6784213-43AD-421A-956C-B2C22096E540

P2093

Q35965389-2BD54E80-6086-4077-A216-42146B7F3919

Q35965389-75721DBF-73D1-4451-A25C-7CA8AB525DF9

Q35965389-B1A02080-9A03-47A5-B36A-AB1B6DEAEF87

Q35965389-DDD77B6D-2D86-4170-9726-E27CC8580A7E

Q35965389-F9A7CE7A-D665-43B1-997B-91BF2D21C372

P2860

Q35965389-3C2E8E07-2A31-45F3-955F-3AE224A1E555

Q35965389-67424C09-8B27-4851-B8D8-A235BF39AF2D

Q35965389-80A7CC87-D8BA-4490-AA05-0DA2481D81C9

Q35965389-AFCFF937-EF3C-4859-BBC0-E9CD89D0E077

Q35965389-BE1B589F-86A2-41D0-AB1B-8C4A1060EBAA

P304

Q35965389-ACC91DA5-1E6B-4636-8858-B2E8D4DFADA5

P31

Q35965389-1871BC6A-A492-4CD9-A73E-AE02530B4AB6

P356

Q35965389-65EED974-788C-40DE-A2ED-2912147A5B3C

P407

Q35965389-A8160825-1086-4397-A2E1-16428468861E

P433

Q35965389-052EA219-02C2-4453-977A-2524A49D7DC4

P478

Q35965389-7D1B8BAB-4F27-4978-A647-63EA1B40A1C1

P577

Q35965389-4BE117A4-7645-4A9C-BEC2-771FD91CA067

P698

Q35965389-53C8F62E-7C65-4196-B67C-933E401FBEA3

P921

Q35965389-BB0FB4E6-A8FD-4D18-BAFC-489F889367B8

P932

Q35965389-1AD3DAB7-BB9E-471B-9879-F8858CAD1928

P356

P1433

The New England Journal of Medicine

P1476

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

@en

P2093

F Stephen Hodi

http://www.w3.org/2001/XMLSchema#string

Hiroto Hatabu

http://www.w3.org/2001/XMLSchema#string

Lynette M Sholl

http://www.w3.org/2001/XMLSchema#string

Mizuki Nishino

http://www.w3.org/2001/XMLSchema#string

Nikhil H Ramaiya

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Soci

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

P304

288-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMC1505197

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26176400

http://www.w3.org/2001/XMLSchema#string

P921

P932

4539956

http://www.w3.org/2001/XMLSchema#string